Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

被引:104
|
作者
Wu, Eric Q. [1 ]
Johnson, Scott [1 ]
Beaulieu, Nicolas [1 ]
Arana, Mateo [1 ]
Bollu, Vamsi [2 ]
Guo, Amy [2 ]
Coombs, John [2 ]
Feng, Weiwei [2 ]
Cortes, Jorge [3 ]
机构
[1] Anal Grp Inc, Boston, MA 02199 USA
[2] Novartis Pharmaceut, Florham Pk, NJ USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
Chronic myeloid leukemia; Cost; Imatinib; Non-adherence; CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; MEDICATION ADHERENCE; BREAST-CANCER; CYTOGENETIC RESPONSES; ADJUVANT TAMOXIFEN; OLDER WOMEN; THERAPY; MESYLATE; PHASE;
D O I
10.1185/03007990903396469
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with chronic myeloid leukemia (CML) who do not adhere to treatment may experience suboptimal outcomes. Objective: To examine the association between adherence with imatinib and direct healthcare costs and resource utilization in a large group of privately insured CML patients. Patients and methods: CML patients under age 65 were identified with ICD-9 code 205.1X using MarketScan Commercial Claims data between 1/1/02 and 7/31/08. Patients were required to be continuously enrolled in a private insurance plan during the baseline and study periods, defined respectively as the 4 months prior to and the 12 months following imatinib initiation. Non-adherence was evaluated by the medication possession ratio (MPR), defined as the fraction of days during the study period that patients had filled prescriptions for imatinib, and stratified into two groups (low MPR: < 85%, high MPR: >= 85%). Costs, inpatient admissions, and hospital days were compared between high and low adherence groups using Wilcoxon tests. Regression models compared utilization and costs controlling for age, sex, CML severity, Charlson comorbidity index, baseline costs, and other factors. Results: The study sample consisted of 592 patients, where 242 (40.9%) patients were classified with a low MPR, while 350 (59.1%) had a high MPR. Mean MPR was 79% (95% confidence interval 76-81%). Patients with a low MPR incurred more all-cause inpatient visits (4.1 vs. 0.4; p < 0.001) and all-cause inpatient days (14.8 vs. 1.8; p < 0.001). Regression models demonstrated a 283% increase (US$56 324; p < 0.001) in non-imatinib costs within the low- vs. high-MPR group. The generalizability of this study is limited by the use of a privately insured population under 65 years of age as well as by the limitations common to claims data analyses. Conclusions: Imatinib adherence is an important issue for patients and physicians. Better imatinib adherence was associated with significantly lower resource utilization and costs in CML patients, as lower imatinib costs in low MPR patients were more than offset by higher non-imatinib costs mostly driven by inpatient services.
引用
收藏
页码:61 / 69
页数:9
相关论文
共 50 条
  • [21] RESOURCE USE AND COSTS ASSOCIATED WITH THE TREATMENT OF ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA (CML) BRAZILIAN PATIENTS
    Alves, M. R.
    Boquimpani, C.
    VALUE IN HEALTH, 2014, 17 (03) : A91 - A91
  • [22] Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia
    Fentie, Atalay Mulu
    Tadesse, Fishatsion
    Engidawork, Ephrem
    Gebremedhin, Am
    PLOS ONE, 2019, 14 (03):
  • [23] Treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs).
    Cai, Beilei
    Broder, Michael
    Chang, Eunice
    Yan, Jessie Tingjian
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
    Atallah, Ehab L.
    Maegawa, Rodrigo
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Guerin, Annie
    Wu, Eric Q.
    Patwardhan, Pallavi
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2022, 9 (02): : 19 - 29
  • [25] Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Stein, Eytan M.
    Latremouille-Viau, Dominick
    Guerin, Annie
    Shi, Sherry
    Gagnon-Sanschagrin, Patrick
    Bonifacio, Gaetano
    Joseph, George J.
    BLOOD, 2016, 128 (22)
  • [26] Resource Use and Costs Associated With The Treatment Of Hematologic and NON-Hematologic Adverse Events In Chronic Myeloid Leukemia (CML) Brazilian Patients
    Alves, Marcia Dias
    Lemos, Marta M.
    Boquimpani, Carla
    BLOOD, 2013, 122 (21)
  • [27] Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics.
    Harnett, J.
    Wiederkehr, D.
    Gerber, R.
    Gruben, D.
    Bourret, J.
    Koenig, A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1049 - S1049
  • [28] NON-ADHERENCE IN CHRONIC MYELOID LEUKEMIA: RESULTS OF A GLOBAL SURVEY OF 2546 CML PATIENTS IN 79 COUNTRIES
    Sharf, G.
    Hoffmann, V.
    Bombaci, F.
    Daban, M.
    Efficace, F.
    Guilhot, J.
    Pelouchova, J.
    Dziwinski, E.
    Jong, J.
    Gavin, A.
    Geissler, J.
    HAEMATOLOGICA, 2013, 98 : 453 - 453
  • [29] Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients
    Clark, Samantha E.
    Marcum, Zachary A.
    Radich, Jerry
    Etzioni, Ruth
    Basu, Anirban
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023,
  • [30] Patients' Perspectives on Adherence to Treatment in Chronic Myeloid Leukemia
    Normen, Michelle
    Surendran, V
    Ganesan, Prasanth
    Rajendranath, Rejiv
    Sagar, T. G.
    PSYCHO-ONCOLOGY, 2013, 22 : 213 - 213